Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR) Sees Significant Decline in Short Interest

Posted by James Quigley on Jul 14th, 2026

Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR – Get Free Report) saw a significant decrease in short interest in June. As of June 30th, there was short interest totaling 65,392 shares, a decrease of 70.6% from the June 15th total of 222,527 shares. Based on an average trading volume of 5,387,370 shares, the short-interest ratio is currently 0.0 days. Currently, 7.1% of the shares of the company are short sold.

Cuprina Holdings (Cayman) Stock Performance

Shares of CUPR traded down $0.10 during mid-day trading on Tuesday, reaching $4.22. 18,032 shares of the company’s stock were exchanged, compared to its average volume of 1,594,912. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 0.07. The stock’s fifty day simple moving average is $3.62. Cuprina Holdings has a 52-week low of $1.76 and a 52-week high of $76.00.

Cuprina Holdings (Cayman) (NASDAQ:CUPR – Get Free Report) last released its quarterly earnings results on Monday, April 27th. The company reported ($0.40) EPS for the quarter. The company had revenue of $0.01 million for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cuprina Holdings (Cayman) in a research report on Friday, April 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Check Out Our Latest Stock Analysis on CUPR

Cuprina Holdings (Cayman) Company Profile

(Get Free Report)

We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. We believe we will be able to build upon and leverage such expertise to develop innovative cosmeceutical products in the future.